{"id":604626,"date":"2022-06-20T19:00:01","date_gmt":"2022-06-20T19:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=604626"},"modified":"2022-06-20T19:00:01","modified_gmt":"2022-06-20T19:00:01","slug":"advanced-pancreatic-cancer-pipeline-analysis-2022-clinical-and-nonclinical-trials-emerging-therapies-and-treatment-algorithm-key-players-eli-lily-fibrogen-ab-science-silenseed-and-pfizer","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/advanced-pancreatic-cancer-pipeline-analysis-2022-clinical-and-nonclinical-trials-emerging-therapies-and-treatment-algorithm-key-players-eli-lily-fibrogen-ab-science-silenseed-and-pfizer_604626.html","title":{"rendered":"Advanced Pancreatic Cancer Pipeline Analysis, 2022 &#8211; Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Players &#8211; Eli Lily, FibroGen, AB Science, Silenseed, and Pfizer"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Advanced Pancreatic Cancer Pipeline Analysis, 2022 - Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Players - Eli Lily, FibroGen, AB Science, Silenseed, and Pfizer\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Advanced Pancreatic Cancer Pipeline Analysis, 2022 - Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Players - Eli Lily, FibroGen, AB Science, Silenseed, and Pfizer\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cAdvanced Pancreatic Cancer Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Pancreatic Cancer Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Advanced Pancreatic Cancer Pipeline<\/strong> report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/34336fc4e3fbe54da9f7e2f43cba9528.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Advanced Pancreatic Cancer Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Advanced Pancreatic Cancer<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Advanced Pancreatic Cancer Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Advanced Pancreatic Cancer key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Advanced Pancreatic Cancer Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Advanced Pancreatic Cancer market<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211; @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Advanced Pancreatic Cancer Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Apart from the already existing players, there are several emerging key players, which are expected to change the dynamics of the locally advanced or metastatic pancreatic cancer market in the coming years owing to the positive outcomes of the emerging pipeline candidates,&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Advanced Pancreatic Cancer Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eli Lily<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">FibroGen&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SynCore Biotechnology&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AB Science&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Silenseed<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AstraZeneca&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pfizer&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NanOlogy&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NantKwest<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ImmunityBio&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PharmaCyte Biotech&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rafael Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Galera Therapeutics&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OSI Pharmaceuticals&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Advanced Pancreatic Cancer Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">NanoPac<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CPI-613<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">GC4419<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Cell-in-a-Box<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Avelumab<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AZD6738<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Masitinib<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">EndoTAG-1<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KRAS (siG12D) LODER<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pamrevlumab (Anti CTGF antibody)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">PD-L1 t-hank and N-803<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Tarceva (erlotinib)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gemzar (gemcitabine)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Advanced Pancreatic Cancer Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Advanced Pancreatic Cancer &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Advanced Pancreatic Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Advanced Pancreatic Cancer Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Advanced Pancreatic Cancer Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Advanced Pancreatic Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Advanced Pancreatic Cancer Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Advanced Pancreatic Cancer Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Advanced Pancreatic Cancer Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Advanced Pancreatic Cancer Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Advanced Pancreatic Cancer Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Advanced Pancreatic Cancer Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/advanced-pancreatic-cancer-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myasthenia-gravis-market\">Myasthenia Gravis Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;Myasthenia Gravis Market&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in 7MM.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=advanced-pancreatic-cancer-pipeline-analysis-2022-clinical-and-nonclinical-trials-emerging-therapies-and-treatment-algorithm-key-players-eli-lily-fibrogen-ab-science-silenseed-and-pfizer\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=advanced-pancreatic-cancer-pipeline-analysis-2022-clinical-and-nonclinical-trials-emerging-therapies-and-treatment-algorithm-key-players-eli-lily-fibrogen-ab-science-silenseed-and-pfizer\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cAdvanced Pancreatic Cancer Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Advanced Pancreatic Cancer Market. The Advanced Pancreatic Cancer Pipeline report embraces in-depth commercial &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/advanced-pancreatic-cancer-pipeline-analysis-2022-clinical-and-nonclinical-trials-emerging-therapies-and-treatment-algorithm-key-players-eli-lily-fibrogen-ab-science-silenseed-and-pfizer_604626.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[426,405,417,406,404],"tags":[],"class_list":["post-604626","post","type-post","status-publish","format-standard","hentry","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=604626"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/604626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=604626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=604626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=604626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}